By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Molecular diagnostics firm OpGen has raised a total of $20 million in its Series B financing round, to be used to advance commercialization of its platform for the generation of de novo whole genome restriction maps.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.
Cancer clinical trial patients settle with Anil Potti and Duke University.
A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.
Two Johns Hopkins researchers discuss the need for evidence-based data analysis.